BLIS Technologies secures two new patents, boosting global IP

BLIS Technologies (NZX: BLT) announced on September 19, 2025, that it has been granted two new patents by the Australian Patent Office. These patents are expected to strengthen BLIS' leadership in oral probiotics and support its global growth strategy.

The first patent covers antiviral applications, protecting the use of *Streptococcus salivarius* K12 and M18 for defending against key upper respiratory viruses, including SARS-CoV-2, Influenza A & B, and RSV. The second patent relates to enhanced formulations, securing proprietary combinations of *Streptococcus salivarius* K12 and M18 with specific prebiotic sugars proven to enhance antimicrobial activity.

According to chief executive Scott Johnson, these patents "cement BLIS' position as a global leader in oral probiotics, unlocking new product opportunities and protecting our science-backed innovation pipeline for long-term growth." This development is set to enable new product development in high-value global health markets, validate the company's R&D leadership, and bolster its competitive edge in the market.